Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cretostimogene Grenadenorepvec · CG-0070

Oncolytic virus (Adenoviral vector) · Kills target cells · developed by CG Oncology

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Cretostimogene Grenadenorepvec?

Cretostimogene grenadenorepvec is a recombinant oncolytic adenovirus that selectively infects and replicates in tumor cells, causing their lysis. It encodes granulocyte-macrophage colony-stimulating factor (GM-CSF), which may promote a cytotoxic T cell response against tumor cells. It is studied in non-muscle invasive bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CG-0070
Drug type
Oncolytic virus (Adenoviral vector)
Mechanism
Kills target cells
Pathways
cytotoxic T cell response, immune-mediated tumor cell death
Therapy area
Oncology
Developer
CG Oncology, Inc.
In trials of
CGON
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
THP9ML4NTZ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04387461 Phase 2 Non Muscle Invasive Bladder Cancer Completed CGON

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non Muscle Invasive Bladder Cancer

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.